1. Home
  2. WWR vs MYO Comparison

WWR vs MYO Comparison

Compare WWR & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

SELL

Current Price

$0.42

Market Cap

53.4M

ML Signal

SELL

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.29

Market Cap

63.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
MYO
Founded
1977
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Industrial Specialties
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.4M
63.8M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
WWR
MYO
Price
$0.42
$1.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$2.17
★ $4.64
AVG Volume (30 Days)
★ 683.7K
238.3K
Earning Date
11-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,000,000,000.00
Revenue This Year
N/A
$11.43
Revenue Next Year
N/A
$12.29
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40814.79
52 Week Low
$0.38
$0.61
52 Week High
$1.51
$1.89

Technical Indicators

Market Signals
Indicator
WWR
MYO
Relative Strength Index (RSI) 37.85 46.90
Support Level $0.39 $1.18
Resistance Level $0.45 $1.75
Average True Range (ATR) 0.02 0.10
MACD 0.00 -0.00
Stochastic Oscillator 45.04 48.28

Price Performance

Historical Comparison
WWR
MYO

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Share on Social Networks: